About Meliora Therapeutics
Meliora Therapeutics is a company based in San Francisco (United States) founded in 2021 by Joan Smith and Jason Sheltzer. Meliora Therapeutics has raised $11 million across 1 funding round from investors including BrightEdge, Axial and HOF Capital. Meliora Therapeutics operates in a competitive market with competitors including Noetik, Function Oncology, Transition Bio, Alixia and OmniSeq, among others.
- Headquarter San Francisco, United States
- Founders Joan Smith, Jason Sheltzer
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Meliora Therapeutics Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$11 M (USD)
in 1 rounds
-
Latest Funding Round
$11 M (USD), Seed
Sep 29, 2022
-
Investors
BrightEdge
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Meliora Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Meliora Therapeutics
Meliora Therapeutics has successfully raised a total of $11M through 1 strategic funding round. The most recent funding activity was a Seed round of $11 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Meliora Therapeutics
Meliora Therapeutics has secured backing from 10 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include BrightEdge, Axial and HOF Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
HOF Capital is engaged in venture capital investments.
|
Locked | Locked | Locked | |
|
Tech & Offline focused Seed stage VC Firm investing primarily in Asia and the US
|
Locked | Locked | Locked | |
|
Provider of venture capital investments across planetary, human, and economic health
|
Locked | Locked | Locked |
Investor details for Meliora Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Meliora Therapeutics
Investment portfolio details for Meliora Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Meliora Therapeutics
Detailed financials for Meliora Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Meliora Therapeutics Comparisons
Peer comparison for Meliora Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Meliora Therapeutics
Meliora Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Noetik, Function Oncology, Transition Bio, Alixia and OmniSeq, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cancer immunotherapies are discovered and developed via AI platform.
|
|
| Locked | Locked | Locked |
Cancer therapeutics are developed using a CRISPR-enabled platform.
|
|
| Locked | Locked | Locked |
Technology platform for biomolecular condensate analysis is developed.
|
|
| Locked | Locked | Locked |
Cancer drug discovery platform is provided for tumor mutation targeting.
|
|
| Locked | Locked | Locked |
Web-based solutions for genomic testing and sequencing access are provided.
|
Detailed competitors of Meliora Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Meliora Therapeutics
Complete news archive for Meliora Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Meliora Therapeutics
Meliora Therapeutics was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Meliora Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Meliora Therapeutics is a funded company, having raised a total of $11M across 1 funding round to date.
Meliora Therapeutics was founded in 2021 and is based in San Francisco, United States. A machine learning-driven platform is developed by the company to support drug discovery in the oncology sector. Operations focus on deciphering potential oncology drugs through advanced algorithms and data analysis. The biotechnology firm targets cancer treatments, with core activities centered on platform-based innovation for pharmaceutical research and development.
Meliora Therapeutics's top competitors include Noetik, Transition Bio and Function Oncology.
Meliora Therapeutics has 10 investors. Key investors include BrightEdge, Axial, HOF Capital, Zhen Fund, and Obvious Ventures.